Scientific Advisory Board

Discovery Research and Translational Biology

Alan D. D’Andrea, M.D.

Chair of IDEAYA SAB | Professor, Harvard Medical School and Member, National Academy of Medicine

Alan D’Andrea, M.D. is the Fuller-American Cancer Society Professor of Medicine at Harvard Medical School and the Director of the Center for DNA Damage and Repair at the Dana-Farber Cancer Institute in Boston. His research is focused on the identification of genetic vulnerabilities in human cancers including leukemia, ovarian, and breast cancer. Dr. D’Andrea is a member of the Board of Scientific Counselors of the National Cancer Institute and is a recipient of the G.H.A. Clowes Award from the American Association of Cancer Research. He currently co-leads the Stand up to Cancer Ovarian Cancer Dream Team with Dr. Elizabeth Swisher.

William R. Sellers, M.D.

Core Institute Member, Broad Institute, Dana-Farber Cancer Institute, and Harvard Medical School

Dr. Sellers is a Core Institute Member at the Broad Institute and faculty member of the Dana-Farber Cancer Institute and Harvard Medical School. From 2005-2016, Dr. Sellers directed cancer drug discovery and early cancer clinical development at the Novartis Institutes for BioMedical Research, during which the oncology research group brought more than 30 cancer therapeutics into first-in-man trials including therapeutics targeting the PI3K, CDK4, IDH, ABL, SMO, HER3, ALK, Wnt, PIM and Ras pathways among others. Along with Dr. Carl June, he co-chaired the CART collaboration with the University of Pennsylvania that brought CTL019 to a recent FDA approval.

Prior to Novartis, Dr. Sellers was an Associate Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School and an Associate Member of the Broad Institute where he initiated large-scale projects which led to discovery of EGFR mutations in lung adenocarcinoma and the discovery of the oncogenic role of the MITF gene in melanoma. In addition, his work advanced the understanding of the molecular mechanisms of growth regulation of the PTEN tumor suppressor gene. Dr. Sellers was a member of the National Cancer Advisory Board from 2011 to 2016. Dr. Sellers received his B.S. from Georgetown University in 1982 and M.D. from the University of Massachusetts Medical School in 1986. He completed residency training in Internal Medicine at the University of California San Francisco in 1989 and trained in Medical Oncology at the Dana-Farber Cancer Institute.

Frank McCormick, Ph.D., FRS, DSc (Hon)

Professor, University of California at San Francisco

Dr. McCormick is a Professor in the University of California, at San Francisco (UCSF), Helen Diller Family Comprehensive Cancer Center and holds the David A. Wood Chair of Tumor Biology and Cancer Research at UCSF. Prior to joining UCSF, Frank was Founder and Chief Scientific Officer at Onyx Pharmaceuticals, building on his earlier research and leadership experiences at Cetus and Chiron. At Onyx, initiated and led drug discovery efforts that led to the approval of Sorafenib for treatment of renal cell cancer and liver cancer. Dr. McCormick has served as President of the American Association for Cancer Research (AACR) and has a leadership role at the Frederick National Lab for Cancer Research, overseeing an NCI supported national effort to develop therapies against Ras-driven cancers.

Trey Ideker, Ph.D.

Professor, University California at San Diego

Trey Ideker, Ph.D., is a Professor in Medicine, Bioengineering and Computer Science at UCSD; Co-Director of the Cancer Genomes and Networks Program at UCSD Moores Comprehensive Cancer Center, and Director of the San Diego Center for Systems Biology. His lab develops technology to build molecular network maps of the cell and to use these networks to translate genotype to phenotype in cancer. He has founded influential bioinformatic tools including Cytoscape, a popular network analysis platform which has been cited >12,000 times. Ideker serves on the Editorial Boards for Cell, Cell Reports, Molecular Systems Biology, and PLoS Computational Biology and is a Fellow of AAAS and AIMBE. He was named one of the Top 10 Innovators of 2006 by Technology Review magazine and was the recipient of the 2009 Overton Prize from the International Society for Computational Biology.

Stephen Kowalczykowski, Ph.D.

Professor, University of California at Davis, and Member, National Academy of Sciences

Stephen Kowalczykowski, Ph.D., is a Distinguished Professor of Microbiology and Molecular Genetics, and of Molecular and Cell Biology at the University of California at Davis. He received his Ph.D. in chemistry and biochemistry with Dr. Jacinto Steinhardt at Georgetown University. His postdoctoral training was with Dr. Peter von Hippel at the University of Oregon. Dr. Kowalczykowski started his independent faculty career in 1981 at Northwestern University Medical School. In 1991, he relocated to the University of California at Davis with the rank of Full Professor. He subsequently served as the Chair of Microbiology and the Director of the Center for Genetics and Development. Dr. Kowalczykowski’s honors include election to the National Academy of Sciences (2007), the American Academy of Arts and Sciences (2005), the American Academy of Microbiology (2003), and the American Association for the Advancement of Science (2001). Dr. Kowalczykowski’s research programs focus on the molecular mechanisms of recombinational DNA repair; the function of homologous recombination in the maintenance of genomic integrity.

John Petrini, Ph.D.

Member, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center

John Petrini, Ph.D., is a Member in the Molecular Biology Program of the Sloan Kettering Institute at the Memorial Sloan Kettering Cancer Center in New York, and the founding Director of the Functional Genomics Initiative at MSKCC. Dr. Petrini received his Ph.D. in 1988 from the University of Michigan Medical School, Ann Arbor, MI, and conducted postdoctoral work at the Dana Farber Cancer Institute at the Harvard Medical School. He began his independent research career at the University of Wisconsin in 1994, and was recruited to MSKCC in 2002. The work in Dr. Petrini’s lab is focused on the DNA damage response, a network of functions comprising DNA damage signaling, DNA repair, and DNA damage dependent cell cycle regulation. His laboratory employs yeast and mice to undertake genetic, molecular biological, and biochemical analyses of the pathways in eukaryotic cells that are responsive to chromosome breaks.

Laura Shawver, Ph.D.

President and CEO, Synthorx

Laura Shawver, Ph.D. is president, chief executive officer, and director of Synthorx. Prior to joining Synthorx, Dr. Shawver held the following positions: CEO and director of Cleave Biosciences, entrepreneur-in-residence for 5AM Ventures, CEO and director of Phenomix Corporation, and president of SUGEN Inc. (acquired by Pharmacia). Shawver has been involved with a number of clinical development programs including two FDA-approved therapies. Shawver is currently a director of Relay Therapeutics as well as an advisor to the industry. She is an active member of the American Association for Cancer Research serving on the Scientific Advisory Committee for Stand Up to Cancer. Shawver knows firsthand what it is like to be a cancer patient. Having survived ovarian cancer, she turned that experience into the founding of The Clearity Foundation, a nonprofit organization providing access to molecular profiling for ovarian cancer patients to improve their treatment options. Shawver received her Ph.D. in pharmacology and a B.S. degree in microbiology both from the University of Iowa.

Clinical Development

Brian Daniels, M.D.

Director | Former SVP, Global Development and Medical Affairs, Bristol-Myers Squibb

Brian Daniels, M.D., served as Senior Vice President of Global Development and Medical Affairs and Research and Development of Bristol-Myers Squibb Co. from March 2008 to July 1, 2014. He served as Senior Vice President of Global Clinical Development, Research and Development of Bristol-Myers Squibb Co. from 2004 to 2008. He also served as a Member of Management Council at Bristol-Myers Squibb Company. He held positions directing and conducting clinical research at Merck and Genentech. He directed the development of innovative medicines, including Apixaban®, Onglyza®, Myalept® and Farxiga® (CV/metabolics), Orencia® and Nulogix® (immunology), Abilify®(neuroscience), Baraclude®, Reyataz®, Daclatasvir® and Asunaprevir® (virology) and Sprycel®, Ixempra®, Yervoy®, elotuzumab and nivolumab (oncology). He serves on the Board of Directors of Novo Nordisk, among others. He completed residency programs at The New York Hospital of Cornell Medical College and at UCSF. Dr. Daniels has an M.D. from Washington University and an M.S. and B.S. from MIT.

Elizabeth Swisher, M.D.

Professor, University of Washington

Elizabeth Swisher, M.D., is a gynecologic oncologist, Professor of Gynecologic Oncology, and adjunct Professor of Medical Genetics at the University of Washington in Seattle. Dr. Swisher’s research focused on understanding the role of the BRCA-Fanconi anemia pathway in ovarian cancer and how defects in DNA repair can be exploited in the therapy and prevention of ovarian carcinoma. She is co-Leader of Stand up to Cancer’s first Ovarian Cancer Dream Team. She is principal investigator on several PARP inhibitor therapeutic trials and collaborates on the translational research for numerous other clinical trials in ovarian and other cancers.

Lawrence Fong, M.D.

Co-Leader, Cancer Immunotherapy Program, and Efim Guzik Distinguished Professor in Cancer Biology at UCSF

Dr. Lawrence Fong is Co-Leader, Cancer Immunotherapy Program, and Efim Guzik Distinguished Professor in Cancer Biology at the Helen Diller Cancer Center at UCSF. Dr. Fong’s laboratory is focused on how the immune system interacts with cancer, investigating how immunotherapies such as immune checkpoint inhibitors and cancer vaccines can enhance anti-tumor immunity in patients. Dr. Fong is also co-director and medical director of the Parker Institute of Cancer Immunotherapy (PICI) at UCSF. He has served on National Cancer Institute (NCI) Steering Committees for Genitourinary Cancer (GUSC) and Investigational Drugs (IDSC)-Immunotherapy Task Force, and is a senior editor for Cancer Immunology Research. Dr. Fong is also the site principal investigator at UCSF for the NCI-sponsored Cancer Immunotherapy Trials Network (CITN). Dr. Fong received his B.A. degree from Columbia University and his M.D. degree from Stanford University, and completed an oncology fellowship at Stanford before joining the medical staff there in 1999. He joined UCSF in 2002.